^
    Back
    Association details:
    Biomarker:miR-21 underexpression
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)

    Published date:
    10/01/2018
    Excerpt:
    RAS wt population with low miR-21 expression (n = 146) showed a significantly higher ORR when cet instead of bev was added to FOLFIRI chemotherapy (80.0% vs. 57.9%; p = 0.005).
    DOI:
    https://doi.org/10.1093/annonc/mdy269.122
    Trial ID:
    FIRE-3